Patents Examined by Alyssa Rae Stonebraker
  • Combination MCL-1 inhibitors with anti-body drug conjugates
    Patent number: 11931424
    Abstract: The present disclosure generally relates to methods of treating or preventing cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate, and optionally one or more additional anti-cancer agents. In particular, the MCL-1 inhibitor can be a compound of formula (I), (II) or (III), or compound A. The antibody-drug conjugate can comprises an anti-Trop-2 antibody and an anti-cancer agent (e.g., SN-38). The combination therapy for treating cancer can have synergistic effect.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: March 19, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • Human interleukin-4 receptor alpha antibodies
    Patent number: 11891441
    Abstract: The present disclosure relates to antibodies that specifically bind human IL-4R?, compositions comprising such IL-4R? antibodies, and methods of using such IL-4R? antibodies.
    Type: Grant
    Filed: August 5, 2022
    Date of Patent: February 6, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Shane Krummen Atwell, Yiqing Feng, Maya Rachel Karta, Donmienne Leung, Songqing Na, Diana Isabel Ruiz, David John Stokell, Laura Anne Pelletier